GlassScriptPhysician profile
Ramakrishna T Reddy
NPI 1457360950
$12,613.05
in general payments reported to CMS, 2019-2025
44 companies · $2,235 in 2025
The $2,235 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,868 · 2020: $1,175 · 2021: $656 · 2022: $1,287 · 2023: $2,614 · 2024: $2,778 · 2025: $2,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,621 · Education: $6.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,621.10 |
| Education | $6.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,284.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $909.01 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $896.51 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $895.40 | 2019-2025 | |
| Amgen INC. | $876.99 | 2019-2025 | Repatha, Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $849.16 | 2019-2025 | Camzyos, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $741.49 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $716.67 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $639.93 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $612.36 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $600.72 | 2020-2025 | Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $509.37 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $263.37 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $250.72 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Kestra Medical Technology Services, INC. | $229.75 | 2025 | Assure Wcd |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $221.99 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $203.01 | 2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $174.84 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $161.49 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $154.61 | 2022-2024 | Amvuttra |
| Cvrx, INC. | $134.41 | 2023-2025 | Barostim Neo System |
| Abiomed | $126.24 | 2022 | |
| Dexcom, INC. | $121.37 | 2022 | |
| Boston Scientific Corporation | $111.34 | 2019-2025 | Watchman Flx, Bodyguardian |
| Scpharmaceuticals INC. | $109.03 | 2024-2025 | |
| Glaxosmithkline, LLC. | $107.05 | 2019-2025 | Arexvy, Shingrix |
| Akcea Therapeutics, INC. | $94.56 | 2019-2020 | |
| Abbott Laboratories | $70.46 | 2020-2024 | Mitraclip |
| Philips North America LLC | $67.30 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
| Sanofi-Aventis U.S. LLC | $62.43 | 2019 | |
| Vertiflex, INC. | $61.06 | 2019 | |
| Sanofi Pasteur INC. | $41.62 | 2019-2020 | |
| Astellas Pharma US INC | $41.39 | 2021-2025 | Veozah |
| Regeneron Healthcare Solutions, INC. | $39.53 | 2019 | |
| Azurity Pharmaceuticals, INC. | $33.87 | 2025 | Edarbi |
| Abbvie INC. | $28.89 | 2023 | |
| W. L. Gore & Associates, INC. | $28.24 | 2020 | |
| Amicus Therapeutics, INC. | $24.22 | 2020 | |
| Sun Pharmaceutical Industries INC. | $22.31 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.00 | 2021 | |
| Ibsa Pharma INC. | $21.05 | 2024 | Tirosint, Licart |
| Scilex Pharmaceuticals INC. | $19.33 | 2019 | |
| Tactile Systems Technology INC | $18.01 | 2023 | Entre Plus, Flexitouch Plus |
| Avanir Pharmaceuticals, INC. | $15.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramakrishna Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.